Asset Details
Do you wish to reserve the book?
In silico design of novel precision vaccine targeting sclerostin epitopes for osteoporosis prevention and treatment
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
In silico design of novel precision vaccine targeting sclerostin epitopes for osteoporosis prevention and treatment
Do you wish to request the book?
In silico design of novel precision vaccine targeting sclerostin epitopes for osteoporosis prevention and treatment
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
In silico design of novel precision vaccine targeting sclerostin epitopes for osteoporosis prevention and treatment
2025
Overview
Osteoporosis has become an increasingly pressing global public health challenge. Monoclonal antibody romosozumab (ROMO), which targets sclerostin (SOST), a critical inhibitor of bone formation, demonstrates considerable therapeutic efficacy. However, its relatively high cost and potential cardiovascular risks may hinder broader clinical application. Current preventive measures remain inadequate.
This study presents a novel, cost-effective osteoporosis vaccine with dual preventive and therapeutic capabilities, derived from the high-affinity binding epitope of ROMO to SOST. ELISA screening determined that the SOST
region within loop3 domain serves as the primary epitope for ROMO, suggesting a role in skeletal regulation with minimal impact on cardiovascular system. SOST
was conjugated to the diphtheria toxin translocation domain (DTT) to create novel SOST-targeted vaccines.
Immunogenicity assays demonstrated that both DDT-SOST
(DS
) and DDT-SOST
(DS
) elicited strong IgG2 antibody responses comparable to ROMO. Molecular docking studies indicated strong affinities of DS
and DS
for Toll-like receptor 2 (TLR2), enhancing TLR2-mediated humoral B-cell immunity and eliciting synergistic T-helper cell responses. Recombinant expression in Escherichia coli confirmed the successful production of DS
and DS
, with molecular weights of 31.8 kDa and 40.3 kDa, respectively.
experiments showed that the vaccines effectively induced high-titer anti-SOST antibodies in mice, overcoming immune tolerance. Additionally, cell-based assays indicated that antiserum from vaccinated mice inhibited osteoclast differentiation and promoted osteoblast mineralization.
The SOST-targeted vaccination strategy offers a promising and cost-effective approach for the early prevention and sustained management of osteoporosis, demonstrating substantial potential for clinical translation.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
Adaptor Proteins, Signal Transducing - immunology
/ Animals
/ Antibodies, Monoclonal - immunology
/ Antigens
/ Antisera
/ Design
/ Enzyme-linked immunosorbent assay
/ Enzymes
/ Epitopes
/ Female
/ Humans
/ Mice
/ Molecular Docking Simulation
/ Osteoporosis - prevention & control
/ Proteins
/ translocation domain of diphtheria toxin (DTT)
/ vaccine
/ Vaccines
